MedTrace Logo

Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

NCT00494338 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-10-01

No results posted yet for this study

Summary

A multi-center controlled, non-comparative open Phase II trial of docetaxel and celecoxib in patients with metastatic androgen independent prostate cancer where efficacy is measured by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart.

Conditions

Interventions

DRUG

Docetaxel

Sponsors & Collaborators

Principal Investigators

  • Jaderson Lima, M.D. · Sanofi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2005-04-30
Completion
2005-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00494338 on ClinicalTrials.gov